Chembio Diagnostics (NASDAQ:CEMI) Posts Earnings Results, Misses Estimates By $0.05 EPS

Share on StockTwits

Chembio Diagnostics (NASDAQ:CEMI) released its earnings results on Thursday. The company reported ($0.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.05), Fidelity Earnings reports. The firm had revenue of $9.72 million during the quarter. Chembio Diagnostics had a negative net margin of 32.95% and a negative return on equity of 39.62%.

Shares of CEMI traded down $0.47 on Friday, reaching $4.54. The stock had a trading volume of 153,300 shares, compared to its average volume of 50,394. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.98 and a current ratio of 3.38. Chembio Diagnostics has a 12-month low of $4.39 and a 12-month high of $7.90. The firm has a market capitalization of $94.85 million, a price-to-earnings ratio of -8.25 and a beta of 1.68. The company has a 50-day simple moving average of $5.77 and a 200-day simple moving average of $6.15.

A number of research analysts have recently commented on the company. Canaccord Genuity restated a “buy” rating and issued a $10.00 target price on shares of Chembio Diagnostics in a research note on Monday, July 22nd. ValuEngine cut Chembio Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, November 4th.

About Chembio Diagnostics

Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.

Featured Article: What is a front-end load?

Earnings History for Chembio Diagnostics (NASDAQ:CEMI)

Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Upgrades AcelRx Pharmaceuticals  to Strong-Buy
Zacks Investment Research Upgrades AcelRx Pharmaceuticals to Strong-Buy
Urban Edge Properties  Sees Large Increase in Short Interest
Urban Edge Properties Sees Large Increase in Short Interest
The Providence Service  Upgraded at TheStreet
The Providence Service Upgraded at TheStreet
Transportadora de Gas del Sur SA ADR  Short Interest Update
Transportadora de Gas del Sur SA ADR Short Interest Update
Halozyme Therapeutics  Posts Quarterly  Earnings Results
Halozyme Therapeutics Posts Quarterly Earnings Results
SAGE Therapeutics  Issues Quarterly  Earnings Results, Misses Expectations By $0.07 EPS
SAGE Therapeutics Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS


 
© 2006-2019 Zolmax.